Sorafenib (Nexavar(R), BAY 43-9006)-induced Hand-foot Skin Reaction with Facial Erythema
Annals of Dermatology
;
: 119-122, 2011.
Article
in English
| WPRIM
| ID: wpr-110484
ABSTRACT
Sorafenib (Nexavar(R), BAY 43-9006) is a novel, orally administered multi-kinase inhibitor that has recently been approved for the treatment of metastatic renal cell carcinoma. It is also used to delay disease progression in patients with advanced solid organ malignancies and metastatic melanoma. Sorafenib is associated with a relatively high incidence of dermatologic adverse events. The commonly occurring dermatologic adverse events associated with sorafenib include hand-foot skin reaction, facial erythema, splinter subungual hemorrhages, alopecia, pruritus and xerosis. We report here on a case of a 50-year-old man who was diagnosed with metastatic hepatocellular carcinoma. He developed both facial erythema and hand-foot skin reaction after the administration of sorafenib.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Phenylurea Compounds
/
Pruritus
/
Skin
/
Carcinoma, Renal Cell
/
Incidence
/
Niacinamide
/
Carcinoma, Hepatocellular
/
Disease Progression
/
Bays
/
Erythema
Type of study:
Incidence study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Annals of Dermatology
Year:
2011
Type:
Article
Similar
MEDLINE
...
LILACS
LIS